Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for lowering serum glucose|
|Abstract:||A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: ##STR00001## and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.|
|Inventor(s):||Burke; Steven K. (Sudbury, MA), Donovan; Joanne M. (Needham, MA)|
|Assignee:||Genzyme Corporation (Cambridge, MA)|
1. A method for reducing serum glucose levels in a human diabetic patient in need thereof, comprising administering to said patient a therapeutically effective amount of
colesevelam or a pharmaceutically acceptable salt thereof.
2. A method for reducing serum glucose levels in a human diabetic patient in need thereof, comprising administering to said patient a therapeutically effective amount of colesevelam or a pharmaceutically acceptable salt thereof, wherein said colesevelam or pharmaceutically acceptable salt thereof is the only active ingredient administered to the patient.
3. The method of claim 1, wherein a pharmaceutically acceptable salt of colesevelam is administered to the patient.
4. The method of claim 2, wherein a pharmaceutically acceptable salt of colesevelam is administered to the patient.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.